What were the dosing regimens of ivermectin in human cancer clinical trials versus typical antiparasitic doses?

1. Typical antiparasitic dosing: established, low microgram/kg regimens

For human parasitic infections, ivermectin is administered at low microgram-per-kilogram doses—most commonly about 150–200 µg/kg for onchocerciasis, strongyloidiasis and enterobiasis, and at 400 µg/kg for lymphatic filariasis in mass‑drug campaigns—doses that have underpinned decades of global public‑health use ^[1].

2. Preclinical anticancer dosing: multi-milligram/kg exposures in animals produce tumor effects

Laboratory and animal work reporting anticancer actions of ivermectin typically use far larger doses than antiparasitic therapy: mouse xenograft studies that suppressed tumor growth employed ivermectin at roughly 3–5 mg/kg, and many in vitro antitumor effects require micromolar concentrations not reached by standard human doses ^{[2] [6]}.

3. Human safety limits and high‑dose volunteer data: how far have humans been pushed?

Human pharmacology and safety studies tolerating higher exposures exist: healthy volunteer dose‑escalation reached up to about 2 mg/kg without serious adverse reactions in published work, and a non‑oncology clinical report administered subcutaneous ivermectin up to 1.6 mg/kg twice weekly for 12 weeks in a specific neuromuscular context—data points that demonstrate some tolerability of higher doses but are limited in scope and patient types ^{[3] [1]}.

4. Cancer clinical testing: limited trials and the dosing schedules being explored

Large, definitive human cancer trials are lacking, but early-phase and investigator trials are beginning to test higher, intermittent oral schedules in oncology—for example, an immunotherapy‑combination trial in metastatic triple‑negative breast cancer uses oral ivermectin on Days 1–3, 8–10 and 15–17 of each 21‑day cycle alongside PD‑1 axis antibodies—representing an intermittent multi‑day dosing strategy rather than continuous low‑dose exposure ^{[7] [4]}.

5. The pharmacologic gap: concentration, duration, and translational uncertainty

A key tension is pharmacologic: standard antiparasitic doses produce plasma concentrations often an order of magnitude or more below the micromolar levels that show anticancer activity in cell culture, which is why oncology dosing targets either higher per‑kg doses or repeated intermittent schedules to raise tumor exposure while attempting to limit toxicity; whether these schedules achieve therapeutic intratumoral concentrations safely in humans remains an open empirical question ^{[6] [1]}.

6. Safety, clinical evidence and the risk of extrapolation

Regulatory and clinical reviewers emphasize that while ivermectin has a favorable safety record at approved antiparasitic doses, that safety profile cannot be simply extrapolated to higher or prolonged oncologic regimens because risks—neurotoxicity, liver effects and drug interactions—may emerge and because high‑quality randomized efficacy data are absent; responsible clinical development therefore requires carefully dosed phase I studies and monitoring rather than off‑label use driven by preclinical promise ^{[4] [8] [5]}.

7. Implications for repurposing and next steps

The practical upshot is straightforward: antiparasitic dosing is low μg/kg and well characterized, preclinical anticancer activity maps to multi‑mg/kg exposure in animals and micromolar concentrations in vitro, and early human oncology protocols are testing intermittent higher oral dosing (e.g., clustered days in a 21‑day cycle) informed by tolerability studies up to ~2 mg/kg—but until randomized trials show benefit and define safe limits, the two dosing worlds should not be conflated ^{[1] [2] [3] [7] [4]}.